🔎 Trials Near Me

Home › B-Cell Lymphoma › NCT06052826

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

RecruitingPhase 2

Geriatric (G) Assessment Guided Optimization (O) to Accelerate Functional Recovery After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Patients 60 Years and Older With B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma (GOCART)

Who can join

Ages 60 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Ability to provide informed consent
* Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care
* Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures
* Age: \>= 60 years at the time of enrollment
* Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma
* Willing and able to complete study requirements
* Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits

Exclusion Criteria:

* Prior CAR-T therapy
* Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

About the study

This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). A large number of patients diagnosed with cancer are over the age of 60, yet most cancer treatments are developed for younger patients. Therefore, older patients may be less likely to be offered stronger treatments, such as CAR-T therapy, due to possible side effects. Geriatric assessment is a multi-dimensional health assessment tool combining patient reported and objective measures covering physical function, mental processes (cognitive), and nutrition. Pre-treatment assessments may identify weaknesses in older adults and may guide interventions for physical therapy, cognitive changes and nutrition to decrease CAR-T therapy side effects and improve care in older adults with NHL or MM.

What is being tested

Sponsor: City of Hope Medical Center · Participants: 164 · Started: Jun 23, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT06052826

Locations in the U.S.

CaliforniaCity of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
North CarolinaWake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
OhioOhio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.